PL375486A1 - Silny inhibitor proteazy serynowej HCV - Google Patents
Silny inhibitor proteazy serynowej HCVInfo
- Publication number
- PL375486A1 PL375486A1 PL03375486A PL37548603A PL375486A1 PL 375486 A1 PL375486 A1 PL 375486A1 PL 03375486 A PL03375486 A PL 03375486A PL 37548603 A PL37548603 A PL 37548603A PL 375486 A1 PL375486 A1 PL 375486A1
- Authority
- PL
- Poland
- Prior art keywords
- serine protease
- potent inhibitor
- hcv serine
- hcv
- potent
- Prior art date
Links
- 102000012479 Serine Proteases Human genes 0.000 title 1
- 108010022999 Serine Proteases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41494002P | 2002-09-30 | 2002-09-30 | |
US42190402P | 2002-10-29 | 2002-10-29 | |
US43383402P | 2002-12-16 | 2002-12-16 | |
US44366203P | 2003-01-30 | 2003-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL375486A1 true PL375486A1 (pl) | 2005-11-28 |
Family
ID=32074646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03375486A PL375486A1 (pl) | 2002-09-30 | 2003-09-25 | Silny inhibitor proteazy serynowej HCV |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040138109A1 (pl) |
EP (1) | EP1549311A1 (pl) |
JP (1) | JP2006505618A (pl) |
KR (1) | KR20050053709A (pl) |
CN (1) | CN1684683A (pl) |
AU (1) | AU2003278967A1 (pl) |
BR (1) | BR0314828A (pl) |
CA (1) | CA2500259A1 (pl) |
CO (1) | CO5550459A2 (pl) |
EA (1) | EA200500406A1 (pl) |
EC (1) | ECSP055689A (pl) |
MX (1) | MXPA05003365A (pl) |
NO (1) | NO20052130L (pl) |
PL (1) | PL375486A1 (pl) |
TW (1) | TW200412960A (pl) |
WO (1) | WO2004030670A1 (pl) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4080541B2 (ja) | 1996-10-18 | 2008-04-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
US8241274B2 (en) | 2000-01-19 | 2012-08-14 | Medtronic, Inc. | Method for guiding a medical device |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
DE602004031645D1 (de) * | 2003-09-22 | 2011-04-14 | Boehringer Ingelheim Pharma | Makrozyklische peptide mit wirkung gegen das hepatitis-c-virus |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
CA2539575C (en) * | 2003-11-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Method of removing transition metals, especially from metathesis reaction products |
CA2549851C (en) * | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
EP2614709A1 (en) * | 2005-07-18 | 2013-07-17 | Novartis AG | Small animal model for HCV replication |
JP5249028B2 (ja) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
EP1915378A4 (en) | 2005-08-12 | 2009-07-22 | Boehringer Ingelheim Int | VIRUS POLYMERASE INHIBITORS |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
DE602006019323D1 (de) | 2005-10-11 | 2011-02-10 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7456165B2 (en) * | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
EP2177523A1 (en) * | 2007-05-03 | 2010-04-21 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
JP2010526834A (ja) * | 2007-05-10 | 2010-08-05 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規ペプチド阻害剤 |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
WO2009076173A2 (en) | 2007-12-05 | 2009-06-18 | Enanta Pharmaceuticals, Inc. | Fluorinated tripeptide hcv serine protease inhibitors |
US8476257B2 (en) | 2007-12-19 | 2013-07-02 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
SG175692A1 (en) | 2008-04-15 | 2011-11-28 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
SG172848A1 (en) | 2009-01-07 | 2011-08-29 | Scynexis Inc | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
AR075584A1 (es) * | 2009-02-27 | 2011-04-20 | Intermune Inc | COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO. |
EP2429568B1 (en) | 2009-05-13 | 2016-08-17 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis c virus inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
PE20140015A1 (es) | 2010-09-21 | 2014-02-16 | Enanta Pharm Inc | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas |
AU2011352145A1 (en) | 2010-12-30 | 2013-07-18 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608027B1 (en) * | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
-
2003
- 2003-09-16 US US10/663,220 patent/US20040138109A1/en not_active Abandoned
- 2003-09-25 EP EP03770478A patent/EP1549311A1/en not_active Withdrawn
- 2003-09-25 KR KR1020057005439A patent/KR20050053709A/ko not_active Application Discontinuation
- 2003-09-25 CA CA002500259A patent/CA2500259A1/en not_active Abandoned
- 2003-09-25 WO PCT/US2003/030402 patent/WO2004030670A1/en not_active Application Discontinuation
- 2003-09-25 CN CNA038234297A patent/CN1684683A/zh active Pending
- 2003-09-25 MX MXPA05003365A patent/MXPA05003365A/es unknown
- 2003-09-25 PL PL03375486A patent/PL375486A1/pl unknown
- 2003-09-25 JP JP2005500319A patent/JP2006505618A/ja active Pending
- 2003-09-25 AU AU2003278967A patent/AU2003278967A1/en not_active Abandoned
- 2003-09-25 BR BR0314828-9A patent/BR0314828A/pt not_active Application Discontinuation
- 2003-09-25 EA EA200500406A patent/EA200500406A1/ru unknown
- 2003-09-29 TW TW092126847A patent/TW200412960A/zh unknown
-
2005
- 2005-03-18 EC EC2005005689A patent/ECSP055689A/es unknown
- 2005-04-26 CO CO05039556A patent/CO5550459A2/es not_active Application Discontinuation
- 2005-04-29 NO NO20052130A patent/NO20052130L/no unknown
Also Published As
Publication number | Publication date |
---|---|
TW200412960A (en) | 2004-08-01 |
CN1684683A (zh) | 2005-10-19 |
MXPA05003365A (es) | 2005-06-22 |
JP2006505618A (ja) | 2006-02-16 |
US20040138109A1 (en) | 2004-07-15 |
CA2500259A1 (en) | 2004-04-15 |
EP1549311A1 (en) | 2005-07-06 |
ECSP055689A (es) | 2005-07-06 |
NO20052130L (no) | 2005-04-29 |
BR0314828A (pt) | 2005-08-02 |
EA200500406A1 (ru) | 2005-12-29 |
AU2003278967A1 (en) | 2004-04-23 |
CO5550459A2 (es) | 2005-08-31 |
WO2004030670A1 (en) | 2004-04-15 |
KR20050053709A (ko) | 2005-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL375486A1 (pl) | Silny inhibitor proteazy serynowej HCV | |
HK1081196A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
HK1090644A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
HK1098164A1 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
HK1095594A1 (en) | 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
AP2052A (en) | Pseudopolymorphic forms of HIV protease inhibitor | |
EP1590442A4 (en) | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS | |
TWI367211B (en) | Hcv ns-3 serine protease inhibitors | |
GB0125445D0 (en) | Protease Inhibitors | |
EP1590442A3 (en) | Macrocyclic hepatitis c serine protease inhibitors | |
HK1070008A1 (en) | Combination of cytochome p 450 dependent protease inhibitors | |
AU1339302A (en) | Biaryl compounds as serine protease inhibitors | |
EP1499336A4 (en) | PROTEASE INHIBITORS | |
AU2003277891A1 (en) | Hcv ns-3 serine protease inhibitors | |
AU2003247776A8 (en) | Serine protease 16 | |
AU2003269984A8 (en) | Protease inhibitors | |
EP1401453A4 (en) | PROTEASE INHIBITORS | |
EP1551794A4 (en) | UREIDO-SUBSTITUTED ANILINE COMPOUNDS SUITABLE AS SERINPROTEASE INHIBITORS | |
ZA200500560B (en) | Potent inhibitor of HCV serine protease | |
AU2002348465A1 (en) | Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease | |
AU2003292406A8 (en) | Serine protease | |
AU2003263738A8 (en) | Protease inhibitors | |
AU6407701A (en) | Serine protease inhibitors | |
EP1544304A4 (en) | NEW SERINPROTEASE | |
EP1433848A4 (en) | NOVEL PROTEIN MT0039 SERINE PROTEASE INHIBITOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |